Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14959575 | 0.73 | SMN1; SMN2 (0.37) | EGFRPTK2ALDH1A1MAPTTOP2A | |
| SCHEMBL12534603 | 0.73 | ALDH1A1 (0.36) | EGFRPTK2ALDH1A1MAPTTOP2A | |
| SCHEMBL11930011 | 0.73 | KDM4E (0.32) | GAATHRBL3MBTL1KDM4E | |
| SCHEMBL13698407 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL27288786 | 0.72 | ALDH1A1 (0.33) | ALDH1A1GAATHRBL3MBTL1 | |
| SCHEMBL22017933 | 0.71 | MAPT (0.34) | EGFRPTK2ALDH1A1MAPTTOP2A | |
| SCHEMBL23373020 | 0.71 | CHRNB2 (0.36) | — | |
| SCHEMBL2754568 | 0.69 | LMNA (0.33) | MAPTGAATHRBL3MBTL1KDM4E | |
| SCHEMBL11930020 | 0.68 | POLB (0.32) | ALDH1A1 | |
| SCHEMBL12187921 | 0.68 | F2 (0.40) | EGFRPTK2ALDH1A1MAPTTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | EGFR 4188/4885PTK2 3800/4885ALDH1A1 135/4885 |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | EGFR 4237/4885PTK2 4647/4885ALDH1A1 153/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | EGFR 4188/4885PTK2 3800/4885ALDH1A1 135/4885 |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | EGFR 4188/4885PTK2 3800/4885ALDH1A1 135/4885 |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | EGFR 4188/4885PTK2 3800/4885ALDH1A1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.